阿托伐他汀对急性冠脉综合征患者外周血单核细胞合成组织因子和TNF-α的影响

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (1): 98-102.

阿托伐他汀对急性冠脉综合征患者外周血单核细胞合成组织因子和TNF-α的影响

吴旭斌¹, 汤圣兴², 伍广伟¹, 林英忠¹, 胡昌兴¹

¹广西壮族自治区人民医院心内科, 南宁 530021, 广西;
²皖南医学院弋矶山医院心血管内科, 芜湖 241001, 安徽

收稿日期:2008-11-11 修回日期:2008-12-09 出版日期:2009-01-26 发布日期:2020-10-27
作者简介:吴旭斌, 男, 博士, 主治医师, 主要从事心脏介入治疗工作。Tel:15977723820 E-mail:xubinwu@hotmail.com

Effects of atorvastain on tissue factor and tumor necrosis factor-alpha synthesis in peripheral blood monocytes from patients with acute coronary syndrome

WU Xu-bin¹, TANG Sheng-xin², WU Guang-wei¹, LIN Ying-zhong¹, HU Chang-xin¹

¹Department of Cardiology, the People' s Hospital of Guangxi Zhuangzu Autonomous Region, Nanning 530021,Guangxi, China;
²Department of Cardiology, Yijishan Hospital, Wannan Medical College, Wuhu 241001, Anhui, China

Received:2008-11-11 Revised:2008-12-09 Online:2009-01-26 Published:2020-10-27

摘要/Abstract

摘要： 目的: 研究阿托伐他汀对急性冠脉综合征患者外周血单核细胞表达TNF-α、组织因子水平及组织因子活性的影响。方法: 分离急性冠脉综合征患者外周血单核细胞, 分别以不同浓度的阿托伐他汀(0, 0.1, 1, 10 μmol/L) 干预, 共同孵育24 h 后, 用夹心酶联免疫吸附测定法检测细胞培养上清液TNF-α及细胞膜组织因子水平, 用逆转录聚合酶联链反应测定它们mRNA 的表达, 同时用底物发光法检测组织因子的活性。结果: 不同浓度的阿托伐他汀(0, 0.1, 1, 10 μmol/L) 干预后急性冠脉综合征患者外周血单核细胞合成TNF-α分别为(306±40) 、(264±54) 、(229±24) 、(189±44) ng/L, 合成组织因子分别为(5.8±1.3) 、(4.6±0.8) 、(3.7±0.9) 、(2.7±0.5) ng/L 及组织因子的活性分别为(16.2±3.2) 、(7.7±2.8) 、(4.3±0.8) 、(3.8±0.8) pmol/L(均P<0.05) 。结论: 阿托伐他汀呈药物浓度依赖性地减少急性冠脉综合征患者外周血单核细胞合成TNF-α、组织因子及组织因子活性。阿托伐他汀通过抗炎、抗血栓形成而在急性冠脉综合征防治中起重要作用。

关键词: 急性冠脉综合征, 肿瘤坏死因子α, 组织因子, 阿托伐他汀

Abstract: AIM: To explore the effects of atorvastatin on the expression of tissue factor and TNF-α, and the tissue factor activity in peripheral blood monocytes from patients with acute coronary syndrome.METHODS: Monocytes were isolated from patients with acute coronary syndrome and cultured with atorvastatin (0, 0.1, 1, 10 μmol/L) for up to 24 hours.The tissue factor and tumor necrosis factor-alpha antigens in culture medium and cells were measured by enzyme-linked immunosorbent assay.The tissue factor activity was examined by chromogenic substrate assay and the mRNA levels were assessed by reverse-transcriptase polymerase chain reaction.RESULTS: Atorvastatin (0, 0.1, 1, 10μmol/L) dose-dependently decreased the levels of tissue factor [(5.8±1.3), (4.6±0.8), (3.7±0.9) and (2.7±0.5) ng/L, respectively] (P<0.05), and the activity of tissue factor [(16.2±3.2), (7.7±2.8), (4.3±0.8) and (3.8±0.8) pmol/L] (P<0.01) in peripheral blood monocytes from patients with acute coronary syndrome.These alterations were accompanied by a reduction in the levels of TNF-α[(306±40), (264±54), (229±24) and (189±44) ng/L, respectively] (P<0.05 ).CONCLUSION: The findings showed that atorvastatin reduced the tissue factor, TNF-αsynthesis and tissue factor activity in peripheral blood monocytes from patients with acute coronary syndrome, and thus potentially had the preventive and therapeutic effects on acute coronary syndrome.

Key words: acute coronary syndrome, tissue factor, tumour necrosis factor-alpha, atorvastatin

中图分类号:

R541

吴旭斌, 汤圣兴, 伍广伟, 林英忠, 胡昌兴. 阿托伐他汀对急性冠脉综合征患者外周血单核细胞合成组织因子和TNF-α的影响[J]. 中国临床药理学与治疗学, 2009, 14(1): 98-102.

WU Xu-bin, TANG Sheng-xin, WU Guang-wei, LIN Ying-zhong, HU Chang-xin. Effects of atorvastain on tissue factor and tumor necrosis factor-alpha synthesis in peripheral blood monocytes from patients with acute coronary syndrome[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(1): 98-102.

参考文献

[1] Gronholdt ML, Dalager-Pedersen S, Falk E.Coronary atherosclerosis: determinants of plaque rupture[J]. Eur Heart J, 1998, 19(Suppl C):C24-29.
[2] Moreno PR, Lodder RA, Purushothaman KR, et al. Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy[J]. Circulation, 2002, 105(8):923-927.
[3] Maseri A, Fuster V.Is there a vulnerable plaque[J] ?Circulation, 2003, 107(16):2068-2071.
[4] Braunwald E, Antman EM, Beasley JW, et al. ACC AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002:summary article:a report of the American College of Cardiology American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2002, 106(14):1893-1900.
[5] Grip O, Janciauskiene S, Lindgren S.Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes[J]. Inflamm Res, 2002, 51(2):58-62.
[6] Nagata K, Ishibashi T, Sakamoto T, et al. Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes[J]. J Hypertens, 2001, 19(4):775-783.
[7] Shah PK.Mechanisms of plaque vulnerability and rupture[J]. J Am Coll Cardiol, 2003, 41(4 Suppl S):15S-22S.
[8] Lutgens E, van Suylen RJ, Faber BC, et al. Atherosclerotic plaque rupture:local or systemic process l[J] ?Arterioscler Thromb Vasc Bio, 2003, 23(12):2123-2130.
[9] Corsini A, Ferri N, Cortellaro M.Are pleiotropic effects of statins real[J] ? Vasc Health Risk Manag, 2007, 3(5):611-613.
[10] Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial[J]. J Am Coll Cardiol, 2007, 49(12):1272-1278.
[11] Grip O, Janciauskiene S, Lindgren S.Pravastatin downregulates inflammatory mediators in human monocytes in vitro[J]. Eur J Pharmacol, 2000, 410(1):83-92.
[12] Ferro D, Parrotto S, Basili S, et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia[J]. J Am Coll Cardiol,2000, 36(2):427-431.
[13] Cortellaro M, Cofrancesco E, Arbustini E, et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque:the ATROCAP study[J]. Thromb Haemost,2002, 88(1):41-47.

[1]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[2]	庞胜峰, 张晶, 吴宁宁, 李茹, 曹军, 何胜虎. 急性冠脉综合征患者PCI术后短程双联抗栓后单用替格瑞洛的疗效观察[J]. 中国临床药理学与治疗学, 2022, 27(9): 1004-1009.
[3]	梁美芳, 陈庆状, 杨沛群, 王勇. 基于真实世界的阿托伐他汀仿制药和原研药防治缺血性脑卒中/短暂性脑缺血发作的有效性和安全性比较[J]. 中国临床药理学与治疗学, 2022, 27(7): 785-792.
[4]	邓毅凡, 何胜虎, 王大新, 戴承晔, 徐笑挺, 张晶. 依折麦布联合他汀对急性冠脉综合征行急诊介入患者残粒脂蛋白胆固醇及MACE影响的临床研究[J]. 中国临床药理学与治疗学, 2021, 26(9): 1048-1052.
[5]	谢祥妹，黄志红，刘小菊，薛冰，蓝保珠. 叶酸片联合阿托伐他汀治疗对H型高血压患者同型半胱氨酸及颈动脉粥样硬化的影响[J]. 中国临床药理学与治疗学, 2020, 25(4): 455-459.
[6]	刘红丹，殷一红. 麒麟丸预防体外受精胚胎移植术后所致卵巢过度刺激综合征患者的疗效及对血浆相关指标的影响[J]. 中国临床药理学与治疗学, 2020, 25(2): 196-202.
[7]	张倩, 付红, 陈瑾瑾, 朱余兵. IL-33/ST2在急性冠脉综合征中的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(9): 1075-1080.
[8]	黄立佳，黄杨，孔劲松，郑鑫，宫小康，阮建伟，王海宝. 阿托伐他汀钙经STAT1-caspase-3信号轴抑制膝骨关节炎大鼠关节软骨退变的研究[J]. 中国临床药理学与治疗学, 2018, 23(7): 743-748.
[9]	杨亚楠，陈莉梅，陶春蕾. 阿托伐他汀钙片在中国健康受试者的生物等效性试验[J]. 中国临床药理学与治疗学, 2018, 23(11): 1258-1264.
[10]	姜海，姜国志，陈钟，李振江. 姜黄提取物联合阿托伐他汀钙对高脂血症小鼠降血脂作用的研究[J]. 中国临床药理学与治疗学, 2017, 22(1): 48-51.
[11]	张莹，王安才，王新，王德国，邢文. 阿托伐他汀对腹主动脉缩窄性高血压大鼠心肌组织蛋白酶S、K的影响[J]. 中国临床药理学与治疗学, 2016, 21(9): 968-972.
[12]	张宁汝，张恒，李妙男，孙强，王洪巨，汤阳. 高血压合并急性冠脉综合征患者P₄₅₀2C19基因多态性与氯吡格雷抵抗及冠状动脉介入术后近期预后关系探讨[J]. 中国临床药理学与治疗学, 2016, 21(4): 425-431.
[13]	许骥，华琦，郝恒剑，徐东，胡少东，李博宇，刘志，桑成，夏经钢. 术前强化他汀治疗联合碘克沙醇对70岁以上患者PCI术后肾功能的保护作用[J]. 中国临床药理学与治疗学, 2016, 21(1): 82-86.
[14]	周逸, 陈曼华, 何琴, 陈刚, 黄婷, 张辉. 不同强度阿托伐他汀对冠脉斑块作用的比较[J]. 中国临床药理学与治疗学, 2015, 20(8): 938-942.
[15]	陆永娟, 陈芝芸, 严茂祥, 何蓓晖, 朱丹. 阿托伐他汀对非酒精性脂肪性肝病大鼠脂肪细胞因子的影响[J]. 中国临床药理学与治疗学, 2015, 20(5): 520-524.